Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04589403 · ClinicalTrials.gov registry record · Phase 1
1a/1b Study of OPT101 First in Human Study Assessing Safety and Tolerability of 15-mer Peptide.
A Phase 1 study, sponsored by Op-T.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT04589403: Completed Phase 1 study, sponsored by Op-T.
NCT04589403 is a Phase 1 study that has completed, run by Op-T. The registered enrollment target is 14 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04589403, a Phase 1 study, has completed, sponsored by Op-T.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
This is a first-in-human study, Phase 1, randomized, placebo-controlled, double blinded study that will be conducted in 2 parts.
Primary Outcome
Incidence of abnormal vital signs and abnormal laboratory values
Interventions
- DRUG OPT101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2021-02-18 |
| Est. Completion | 2021-09-27 |
| Phase | Phase 1 |
What the finished NCT04589403 record still lists
NCT04589403 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 1 intervention - of which OPT101 is the first listed.
NCT04589403 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04589403 about?
NCT04589403 is a clinical study titled "1a/1b Study of OPT101 First in Human Study Assessing Safety and Tolerability of 15-mer Peptide.". This is a first-in-human study, Phase 1, randomized, placebo-controlled, double blinded study that will be conducted in 2 parts.
What is the current status of trial NCT04589403?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2021-02-18. Estimated completion is 2021-09-27.
What interventions are being tested in trial NCT04589403?
The interventions under investigation include: OPT101 (DRUG).
Who is sponsoring clinical trial NCT04589403?
This trial is sponsored by Op-T, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04589403's enrollment target sits among peer trials
14 1844th of 2000 higher than 154 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy